Strides Pharma Consolidates European Business-to-Business Operations in Switzerland
- Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
- Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board

Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.
Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.
The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.
Oren Weininger, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”
Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.
For further information, please visit: www.fair-med.com/newsroom
Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690
Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.
Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.
Images

Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
ZEISS Lightfield 4D for instant volumetric high-speed imaging6.3.2025 09:40:00 CET | Press release
Capturing physiological and neuronal processes in 3D
DYMO Deutschland: PROFESSIONAL LABELLING ANYWHERE, ANYTIME: DYMO® INTRODUCES NEW LABELMANAGER EXECUTIVE 640 CB3.3.2025 11:19:35 CET | Press release
ATLANTA – DYMO®, a leader in innovative labeling solutions, proudly announces the launch of the new LabelManager Executive 640 CB. It is designed for professionals seeking a fast, efficient, and reliable labeling solution for various work environments, from offices to the medical sector, with a strong emphasis on ease of use. The LabelManager Executive 640 CB enables users to print labels faster, saving valuable time on labeling tasks and boosting productivity across industries. - Picture is available at AP - User-Friendly Design and Versatile Connectivity In today's fast-paced work environment, organization and clarity are crucial. The LabelManager Executive 640 CB addresses these needs with a compact design and a rechargeable lithium-ion battery, making it perfect for both office use and on-the-go labeling. Its high-resolution (240*320 pixels RGB; 143 ppi) display ensures clear and readable labels, while the intuitive menu simplifies label creation and customization. The device offer
OpenCloud: OpenCloud 1.0 now available: New open-source alternative to Microsoft SharePoint & Co.25.2.2025 13:52:10 CET | Press release
Berlin, Germany– Just a few weeks after the operational launch of OpenCloud GmbH, the first full, installable release of OpenCloud is now available. OpenCloud is a modern open-source solution for file management, file sharing and content collaboration, serving as a high-performance, GDPR-compliant alternative to proprietary solutions such as Microsoft SharePoint, Google Drive or Dropbox. With an innovative cloud-native architecture and licensing under Apache 2.0 and AGPL-3.0, OpenCloud offers a future-proof, transparent, and digital sovereign solution for IT infrastructures in Europe. OpenCloud is developed in the programming language Go, offering high performance and scalability. Version 1.0 with web office integration OpenCloud already offers a wide range of advanced features right from the start, including: Secure and scalable file storage solutions Collabora Online integration as a comprehensive web office solution Collaboration tools for seamless real-time editing Detailed user an
Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal24.2.2025 16:08:47 CET | Press release
Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.
Reinhard Mohn Prize awarded to Maia Sandu and Michael Otto20.2.2025 15:00:00 CET | Press release
(Gütersloh, Germany) The Bertelsmann Stiftung today awarded the 2025 Reinhard Mohn Prize to the President of the Republic of Moldova, Maia Sandu, and to entrepreneur and philanthropist Michael Otto. In keeping with the title of this year’s prize – “Strengthen democracy!” – it presented the award in recognition of both recipients’ commitment to democratic values and a free society. At Gütersloh Theater, before an audience of some 500 guests, Germany’s Federal President Frank-Walter Steinmeier and Liz Mohn, honorary member of the Bertelsmann Stiftung’s Board of Trustees and the foundation’s global representative, gave the presentation speeches. The two award winners will share the prize money totaling €200,000 euros and will donate it to non-profit projects and initiatives. The Bertelsmann Stiftung broadcast the ceremony via livestream. “In a crisis-torn world, democracy faces enormous challenges,” said Liz Mohn. “Maintaining, developing and strengthening democracy was one of the key con
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom